What is Genetico?
Based in Russia, the Center for Genetics and Reproductive Medicine, known as Genetico, operates as a specialized medical laboratory providing comprehensive genetic services. The company serves as a vital bridge between complex genomic data and clinical application, offering diagnostic solutions for both medical practitioners and patients. Its market position is defined by a commitment to precision medicine, focusing on hereditary disease screening, reproductive health diagnostics, and personalized therapeutic guidance. As a key entity in the diagnostic infrastructure, Genetico integrates advanced molecular biology techniques to address the growing demand for high-fidelity genetic insights in modern clinical workflows.
How much funding has Genetico raised?
Genetico has raised a total of $2.2M across 1 funding round:
Stock Offering
$2.2M
Stock Issuance/Offering (2023): $2.2M, investors not publicly disclosed
Key Investors in Genetico
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Genetico?
With the successful completion of this major strategic investment, Genetico is poised to enter a new phase of operational maturity. The company is expected to prioritize the enhancement of its diagnostic throughput and the integration of next-generation sequencing capabilities to maintain its competitive edge. Future strategic initiatives will likely focus on broadening its service portfolio to include more sophisticated prenatal and oncology-related genetic testing. By reinforcing its laboratory infrastructure and investing in talent acquisition, Genetico aims to solidify its status as a leader in the regional genetic services market, ultimately driving better patient outcomes through data-driven medical interventions.
See full Genetico company page
